Outlook Therapeutics (OTLK) Non-Current Assets (2015 - 2026)
Outlook Therapeutics (OTLK) posted quarterly Non-Current Assets of $987695.0 for Q1 2026, down 22.11% year-over-year from $1.3 million in Q1 2025, and down 7.87% quarter-over-quarter from $1.1 million in Q4 2025.
Outlook Therapeutics (OTLK) Non-Current Assets (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Non-Current Assets for 12 consecutive years, with $987695.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 22.11% year-over-year to $987695.0; the TTM figure through Mar 2026 stood at $4.6 million (down 17.09% YoY), while the FY2025 annual figure was $1.2 million, down 15.06% from the prior year.
- Non-Current Assets slipped to $987695.0 in Q1 2026 per OTLK's latest filing, from $1.1 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $1.5 million in Q2 2024 and bottomed at $971901.0 in Q1 2023.
- Historically, Non-Current Assets has averaged $1.2 million across 5 years, with a median of $1.2 million in 2024.
- Annual changes were most pronounced in 2022 — Non-Current Assets retreated 22.71% — and 2023, when it surged 33.01%.
- Outlook Therapeutics' Non-Current Assets stood at $1.0 million in 2022, then gained by 27.98% to $1.3 million in 2023, then rose by 3.31% to $1.3 million in 2024, then dropped by 19.92% to $1.1 million in 2025, then retreated by 7.87% to $987695.0 in 2026.
- Business Quant data shows OTLK's Non-Current Assets at $987695.0 in Q1 2026, $1.1 million in Q4 2025, and $1.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.04 Bn | 130.19 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.58 Bn | 77.59 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.34 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 56.52 Bn | 51.38 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.04 Bn | 36.94 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.67 Bn | 27.36 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.27 Bn | 26.11 Bn | 358.27 Mn | 468.65 Mn |
| 8 | BioNTech SE | 27.14 Bn | 8.75 Bn | 668.28 Mn | 6.80 Bn |
| 9 | Royalty Pharma | 27.12 Bn | 26.28 Bn | - | 18.06 Bn |
| 10 | Outlook Therapeutics | 94.53 Mn | 83.29 Mn | -8,265.00 | 3.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 987,695.00 |
| Dec 31, 2025 | 1.07 Mn |
| Sep 30, 2025 | 1.20 Mn |
| Jun 30, 2025 | 1.30 Mn |
| Mar 31, 2025 | 1.27 Mn |
| Dec 31, 2024 | 1.34 Mn |
| Sep 30, 2024 | 1.41 Mn |
| Jun 30, 2024 | 1.47 Mn |
| Mar 31, 2024 | 1.24 Mn |
| Dec 31, 2023 | 1.30 Mn |
| Sep 30, 2023 | 1.32 Mn |
| Jun 30, 2023 | 1.43 Mn |
| Mar 31, 2023 | 971,901.00 |
| Dec 31, 2022 | 1.01 Mn |
| Sep 30, 2022 | 1.01 Mn |
| Jun 30, 2022 | 1.07 Mn |
| Mar 31, 2022 | 1.14 Mn |
| Dec 31, 2021 | 1.21 Mn |
| Sep 30, 2021 | 1.30 Mn |
| Jun 30, 2021 | 984,737.00 |